MedTrace Logo

Monitoring Schistosome Hybrids Under Under Praziquantel Pressure

NCT04635553 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2020-11-19

No results posted yet for this study

Summary

The overall objective of this project is to examine and quantify the potential existence and impact on Praziquantel (PZQ) efficacy, of naturally occurring S. haematobium and S. bovis hybrid populations in northern Senegal. Schistosome hybrids may present vigor compared to their pure parental forms and hence, may be less sensitive to PZQ. We hypothesise that PZQ repeated treatment selects the hybrid schistosome populations.

Conditions

  • Schistosomiasis

Interventions

DRUG

Praziquantel 600 milligram

A single treatment with a dose of 40 milligram/kilogram (mg/kg)

Sponsors & Collaborators

  • Institut de Recherche pour le Developpement

    lead OTHER_GOV

Eligibility

Min Age
5 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-11
Primary Completion
2021-07-31
Completion
2022-12-31

Countries

  • Senegal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04635553 on ClinicalTrials.gov